MX2019003733A - Tratamiento de cancer de prostata. - Google Patents
Tratamiento de cancer de prostata.Info
- Publication number
- MX2019003733A MX2019003733A MX2019003733A MX2019003733A MX2019003733A MX 2019003733 A MX2019003733 A MX 2019003733A MX 2019003733 A MX2019003733 A MX 2019003733A MX 2019003733 A MX2019003733 A MX 2019003733A MX 2019003733 A MX2019003733 A MX 2019003733A
- Authority
- MX
- Mexico
- Prior art keywords
- subject
- prostate cancer
- methoxyurea
- tetrahydrothien
- difluorobenzyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662402004P | 2016-09-30 | 2016-09-30 | |
| US201662402150P | 2016-09-30 | 2016-09-30 | |
| PCT/EP2017/074849 WO2018060463A2 (en) | 2016-09-30 | 2017-09-29 | Treatment of prostate cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019003733A true MX2019003733A (es) | 2019-09-26 |
Family
ID=60915459
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019003733A MX2019003733A (es) | 2016-09-30 | 2017-09-29 | Tratamiento de cancer de prostata. |
| MX2023001468A MX2023001468A (es) | 2016-09-30 | 2019-03-29 | Tratamiento de cancer de prostata. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001468A MX2023001468A (es) | 2016-09-30 | 2019-03-29 | Tratamiento de cancer de prostata. |
Country Status (21)
| Country | Link |
|---|---|
| US (7) | US10449191B2 (enExample) |
| EP (2) | EP3518932B1 (enExample) |
| JP (1) | JP7062673B2 (enExample) |
| CN (1) | CN110248661A (enExample) |
| AU (2) | AU2017334035B2 (enExample) |
| BR (1) | BR112019006228A2 (enExample) |
| CA (1) | CA3038875A1 (enExample) |
| DK (1) | DK3518932T3 (enExample) |
| ES (1) | ES3002857T3 (enExample) |
| FI (1) | FI3518932T3 (enExample) |
| HR (1) | HRP20241740T1 (enExample) |
| HU (1) | HUE070578T2 (enExample) |
| IL (3) | IL308528A (enExample) |
| LT (1) | LT3518932T (enExample) |
| MA (1) | MA46361A (enExample) |
| MX (2) | MX2019003733A (enExample) |
| NZ (1) | NZ752918A (enExample) |
| PL (1) | PL3518932T3 (enExample) |
| PT (1) | PT3518932T (enExample) |
| SI (1) | SI3518932T1 (enExample) |
| WO (1) | WO2018060463A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3415517T (pt) | 2012-09-28 | 2022-05-13 | Takeda Pharmaceuticals Co | Forma cristalina de 1-(4-1-(2,6-difluorobenzil)-5- dimetilaminometil-3-(6-metoxipiridazin-3-il)-2,4-dioxo- 1,2,3,4-tetrahidrotieno(2,3-d)-pirimidin-6-il)fenil)-3- metoxiureia |
| EP3518932B1 (en) | 2016-09-30 | 2024-11-13 | Sumitomo Pharma Switzerland GmbH | Treatment of prostate cancer |
| ES2912929T5 (en) | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
| CN110194776B (zh) * | 2019-06-27 | 2021-05-28 | 四川伊诺达博医药科技有限公司 | 一种瑞卢戈利的合成方法 |
| CN115279769A (zh) | 2019-10-10 | 2022-11-01 | 梦欧文科学有限责任公司 | N-(4-(1-(2,6-二氟苄基)-5-((二甲基氨基)甲基)-3-(6-甲氧基-3-哒嗪基)-2,4-二氧代-1,2,3,4-四氢噻吩并[2,3-d]嘧啶-6-基)苯基)-n’-甲氧基脲的结晶形式 |
| EP4041738A1 (en) * | 2019-10-10 | 2022-08-17 | Myovant Sciences GmbH | Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| CA3185151A1 (en) | 2020-05-29 | 2021-12-02 | Myovant Sciences Gmbh | Combination solid oral dosage forms of gonadotropin-releasing hormone antagonists |
| EP4232164A4 (en) * | 2020-10-20 | 2025-01-15 | Baylor College of Medicine | MULTIPLEX METABOLIC MARKERS IN PLASMA FOR EARLY DETECTION OF AFRICAN AMERICAN PROSTATE CANCER |
| EP4243829A1 (en) * | 2020-11-11 | 2023-09-20 | Myovant Sciences GmbH | Methods of administering relugolix |
| EP4419530A1 (en) | 2021-10-18 | 2024-08-28 | Sumitomo Pharma Switzerland GmbH | Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea |
| WO2023152611A1 (en) * | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2710637B1 (fr) | 1993-09-28 | 1995-12-08 | Roquette Freres | Mannitol pulvérulent de friabilité modérée et son procédé de préparation. |
| RU2233284C2 (ru) | 1999-03-24 | 2004-07-27 | Такеда Кемикал Индастриз, Лтд. | Тиенопиримидиновые производные, способ их получения, фармацевтическая композиция и способ антагонизации гонадотропин-рилизинг гормона |
| TWI225863B (en) | 1999-03-24 | 2005-01-01 | Takeda Chemical Industries Ltd | Thienopyrimidine compounds, their production and use |
| WO2001064683A1 (en) | 2000-02-29 | 2001-09-07 | Takeda Chemical Industries, Ltd. | Processes for the production of thienopyrimidine derivatives |
| WO2003057689A1 (en) | 2002-01-02 | 2003-07-17 | Fujisawa Pharmaceutical Co., Ltd. | Aminopyrimidine compounds, processes for their preparation and pharmaceutical compositions containing them |
| WO2003064429A1 (en) | 2002-01-30 | 2003-08-07 | Takeda Chemical Industries, Ltd. | Thienopyrimidines, process for preparing the same and use thereof |
| PL208114B1 (pl) | 2002-02-26 | 2011-03-31 | Astrazeneca Ab | Kompozycja farmaceutyczna, sposób jej wytwarzania i zastosowanie |
| PT1591446E (pt) | 2003-01-29 | 2013-06-12 | Takeda Pharmaceutical | Compostos de tienopirimidina e sua utilização |
| CA2531508C (en) | 2003-07-07 | 2013-10-08 | Neurocrine Biosciences, Inc. | Pyrimidine-2, 4-dione derivatives as gonadotropin-releasing hormone receptor antagonists |
| KR20080041662A (ko) | 2005-07-22 | 2008-05-13 | 다케다 야쿠힌 고교 가부시키가이샤 | 조기 배란 예방제 |
| NZ580457A (en) | 2007-04-06 | 2012-03-30 | Neurocrine Biosciences Inc | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto |
| US8765948B2 (en) | 2007-11-07 | 2014-07-01 | Neurocrine Biosciences, Inc. | Processes for the preparation of uracil derivatives |
| TWI442932B (zh) | 2008-02-11 | 2014-07-01 | Ferring Int Ct Sa | 以ＧｎＲＨ拮抗劑治療攝護腺癌的方法 |
| WO2010026993A1 (ja) | 2008-09-03 | 2010-03-11 | 武田薬品工業株式会社 | 製剤における吸収性改善方法および吸収性が改善された製剤 |
| PT3415517T (pt) | 2012-09-28 | 2022-05-13 | Takeda Pharmaceuticals Co | Forma cristalina de 1-(4-1-(2,6-difluorobenzil)-5- dimetilaminometil-3-(6-metoxipiridazin-3-il)-2,4-dioxo- 1,2,3,4-tetrahidrotieno(2,3-d)-pirimidin-6-il)fenil)-3- metoxiureia |
| EP3185881B1 (en) | 2014-08-26 | 2022-03-09 | Betanien Hospital | Methods, agents and compositions for treatment of inflammatory conditions |
| FI3263110T3 (fi) | 2015-02-26 | 2023-07-25 | Takeda Pharmaceuticals Co | Tabletti, joka käsittää metoksiureajohdannaista ja mannitolipartikkeleita |
| US9949974B2 (en) | 2015-09-01 | 2018-04-24 | Abbvie Inc. | Methods of adminstering elagolix |
| US20180044977A1 (en) | 2016-08-12 | 2018-02-15 | Raynor Mfg. Co. | Rolling door construction for controlling air leakage |
| EP3518932B1 (en) | 2016-09-30 | 2024-11-13 | Sumitomo Pharma Switzerland GmbH | Treatment of prostate cancer |
| ES2912929T5 (en) | 2016-09-30 | 2025-05-09 | Sumitomo Pharma Switzerland Gmbh | Methods of treating uterine fibroids and endometriosis |
-
2017
- 2017-09-29 EP EP17823017.3A patent/EP3518932B1/en active Active
- 2017-09-29 HR HRP20241740TT patent/HRP20241740T1/hr unknown
- 2017-09-29 SI SI201731574T patent/SI3518932T1/sl unknown
- 2017-09-29 ES ES17823017T patent/ES3002857T3/es active Active
- 2017-09-29 CA CA3038875A patent/CA3038875A1/en active Pending
- 2017-09-29 DK DK17823017.3T patent/DK3518932T3/da active
- 2017-09-29 JP JP2019538720A patent/JP7062673B2/ja active Active
- 2017-09-29 WO PCT/EP2017/074849 patent/WO2018060463A2/en not_active Ceased
- 2017-09-29 FI FIEP17823017.3T patent/FI3518932T3/fi active
- 2017-09-29 BR BR112019006228A patent/BR112019006228A2/pt not_active Application Discontinuation
- 2017-09-29 CN CN201780072970.4A patent/CN110248661A/zh active Pending
- 2017-09-29 NZ NZ752918A patent/NZ752918A/en unknown
- 2017-09-29 MX MX2019003733A patent/MX2019003733A/es unknown
- 2017-09-29 PL PL17823017.3T patent/PL3518932T3/pl unknown
- 2017-09-29 HU HUE17823017A patent/HUE070578T2/hu unknown
- 2017-09-29 LT LTEPPCT/EP2017/074849T patent/LT3518932T/lt unknown
- 2017-09-29 IL IL308528A patent/IL308528A/en unknown
- 2017-09-29 PT PT178230173T patent/PT3518932T/pt unknown
- 2017-09-29 AU AU2017334035A patent/AU2017334035B2/en active Active
- 2017-09-29 IL IL300071A patent/IL300071A/en unknown
- 2017-09-29 MA MA046361A patent/MA46361A/fr unknown
- 2017-09-29 EP EP24212224.0A patent/EP4520398A3/en active Pending
-
2019
- 2019-03-28 IL IL265697A patent/IL265697B2/en unknown
- 2019-03-29 US US16/369,729 patent/US10449191B2/en active Active
- 2019-03-29 MX MX2023001468A patent/MX2023001468A/es unknown
- 2019-09-06 US US16/563,161 patent/US10786501B2/en active Active
-
2020
- 2020-08-20 US US16/998,900 patent/US11583526B2/en active Active
-
2022
- 2022-07-15 US US17/866,203 patent/US12097198B2/en active Active
-
2023
- 2023-02-22 AU AU2023201047A patent/AU2023201047B2/en active Active
-
2024
- 2024-06-28 US US18/758,904 patent/US12144809B1/en active Active
- 2024-11-05 US US18/937,891 patent/US12336990B2/en active Active
- 2024-11-25 US US18/959,460 patent/US20250082632A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4520398A3 (en) | Treatment of prostate cancer | |
| EA200501849A1 (ru) | Производные пиразолохиназолина: способ получения и применение в качестве ингибиторов киназ | |
| PE20160195A1 (es) | Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington | |
| AR048431A1 (es) | Formulaciones galenicas de compuestos organicos | |
| RU2016129953A (ru) | Фармацевтические комбинации | |
| HRP20220718T1 (hr) | Kombinacijska terapija uključujući inhibitor mdm2 i jedan ili više dodatnih farmaceutski aktivnih sredstava za liječenje raka | |
| ECSP088974A (es) | Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3) | |
| RU2017102319A (ru) | Прерывистое введение ингибитора mdm2 | |
| JOP20240235A1 (ar) | مركبات أريل غير متجانسة لمعالجة الألم | |
| MX2013010770A (es) | Tratamiento de tumores solidos. | |
| MX374724B (es) | Derivados de carbazol. | |
| MX2018005715A (es) | Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash. | |
| PE20211818A1 (es) | Composicion farmaceutica para administracion oral que comprende derivado de aminopirimidina o su sal | |
| MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
| MX2021015543A (es) | Derivado de pirimidina que inhibe el crecimiento de celulas cancerosas y uso medicinal del mismo. | |
| ZA202000028B (en) | Use of vibegron to treat overactive bladder | |
| AR080096A1 (es) | Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| MX2022008216A (es) | Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo. | |
| EA200501166A1 (ru) | Составы и способы лечения тромбоцитемии | |
| MX2022016406A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un inhibidor de hif-2 alpha y lenvatinib. | |
| JOP20210320A1 (ar) | طرق علاج السرطان باستخدام مثبطات prmt5 | |
| AR039895A1 (es) | Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla | |
| ATE485037T1 (de) | Krebsbehandlung mittels fts und 2-deoxyglucose | |
| MX2022016410A (es) | Metodos para tratar el cancer o enfermedad de von-hippel lindau usando una combinacion de un antagonista del pd-1, inhibidor de hif-2 alpha y lenvatinib o una sal aceptable farmeuticamente de estos. |